Fondation Ophtalmologique A. de Rothschild
Paris, 75019, France
NCT Number: NCT02381951
Parkinson's disease affects between 100'000 and 150'000 people in France. Drug therapy (L-Dopa and other drugs) is effective to improve motor symptoms but after an initial 'honeymoon period' lasting a few years, motor symptoms reoccur in most patients, impairing gait and walking.
Spinal cord stimulation is currently an important therapeutic option in the treatment of neuropathic pain. Experimental and limited clinical data suggest that this technique might also be used to alleviate motor symptoms and improve walking in Parkinsons patients.
This exploratory study aims at measuring the benefits of spinal cord stimulation on the walking capacity of a small number of Parkinsons patients who are not adequately improved by drug therapy alone.
Looking for future studies?
Notify Me40 year–75 year
All sexes
Interventional
Not applicable
Paris, 75019, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
implantation of a spinal cord neurostimulation system : St Jude Medical Octrode 3183 (R) peridural lead connected to a St Jude Medical EonC (R) primary cell IPG
Time frame: 2 months
"stand-walk-sit" test : time to complete the test : difference between scores pre-implantation and 2 month post-implantation of stimulator
Time frame: 2 months
"stand-walk-sit" test : total number of freezing episodes during the test : difference between scores pre-implantation and 2 month post-implantation of stimulator
Time frame: 2 months
"stand-walk-sit" test : cumulated time of freezing episodes during the test : difference between scores pre-implantation and 2 month post-implantation of stimulator
Time frame: 2 months
percentage of improvement in the motor score (part III of scale) of MultiDimentionalScaling-UPDRS scale, between score pre-implantation and score 2 months post-implantation of stimulator
Time frame: 2 months
percentage of improvement in the "freezing of gate" score, between score pre-implantation and score 2 months post-implantation of stimulator
Time frame: 2 months
improvement in PDQ 39 quality of life score between pre-implantation visit and 2 months post-implantation of stimulator
Fondation Ophtalmologique Adolphe de Rothschild
Network
Acronym: STIMUPARK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03648905
Autonomic Failure, Autonomic Nervous System Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT01621581
Basal Ganglia Diseases, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT05699460
Autonomic Nervous System Diseases, Basal Ganglia Diseases
Irvine, California, United States
View Trial DetailsNCT07720869
Basal Ganglia Diseases, Brain Diseases
Baton Rouge, Louisiana, United States
View Trial Details